Trials / Completed
CompletedNCT01264497
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Theratechnologies · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TH9507 | 1 and 2 mg, sc daily for 12 weeks |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2002-11-01
- Completion
- 2002-11-01
- First posted
- 2010-12-21
- Last updated
- 2010-12-21
Source: ClinicalTrials.gov record NCT01264497. Inclusion in this directory is not an endorsement.